Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published April 2018 | Published
Journal Article Open

Bloom syndrome: research and data priorities for the development of precision medicine as identified by some affected families

Abstract

Bloom syndrome (BS) is a rare, autosomal recessive genetic disorder characterized by short stature, a skin rash associated with sun exposure, and an elevated likelihood of developing cancers of essentially all types, beginning at an early age. Cancer is the leading cause of death for persons with BS, and its early onset results in a reported median lifespan of <30 years. With fewer than 300 documented cases since BS was first described in 1954, its rarity has challenged progress in advancing both the care of and the cure for persons with BS. Presently, there are no known clinically actionable targets specific to persons with this cancer predisposition syndrome, despite the fact that standard cancer treatments are often contraindicated or must be substantially modified for persons with BS. Herein, Zachary Rogers recounts his experience as a cancer patient with BS contemplating a substantially customized chemotherapy regimen that highlights the need for development of individualized treatments in the BS community. We also outline a patient-centered research and community action road map with the goal of improving and prolonging the lives of persons with Bloom syndrome, including the facilitation of precision medicine development specific to this condition.

Additional Information

© 2018 Campbell et al.; Published by Cold Spring Harbor Laboratory Press This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted reuse and redistribution provided that the original author and source are credited. We thank the Children's Cancer Therapy Development Institute and its Scientific Director, Dr. Charles Keller, for all of their work in hosting the 2017 Pediatric Cancer Nanocourse. We also thank the Bloom Syndrome speakers at the Nanocourse, including Dr. Chris Cunniff, Dr. Nathan Ellis, Dr. Mark Osborn, and Dr. Sharon Plon, for participating. The authors have declared no competing interest.

Attached Files

Published - Cold_Spring_Harb_Mol_Case_Stud-2018-Campbell-.pdf

Files

Cold_Spring_Harb_Mol_Case_Stud-2018-Campbell-.pdf
Files (1.2 MB)

Additional details

Created:
August 19, 2023
Modified:
October 18, 2023